After delay, CSL's $11.7B deal for Vifor poised to close next week

After an antitrust review knocked 2021’s biggest biopharma buyout off course in May, CSL’s $11.7 billion deal for Swiss iron deficiency specialist Vifor Pharma appears to be back on track.